Recombinant Proteins Market is projected to cross USD 9 billion by the end of 2035, growing at a CAGR of 12.80% during the forecast period , i.e., 2023-2035. The market growth is mainly owing to the increasing demand for biopharmaceuticals, advancements in biotechnology, and rising prevalence of chronic diseases across the globe. Moreover, diabetes, which is a chronic disease, is one of the most prevalent diseases across the globe. Diabetes damages many organs in the body, including the eyes, nerves, brain, kidneys, heart, and blood vessels. Rise in adults with chronic disease and diabetes is expected to increase the demand for recombinant proteins during the forecast period. For instance, in the year 2021 it was noted that more than 530 million adults have diabetes, which is expected to rise to about 640 million by the year 2030. Hence, this is also expected to be a major factor to add to the growth of the global market.
In addition to this, biopharmaceuticals represent one of the fastest-growing sectors within the pharmaceutical industry, with a projected global revenue size of nearly USD 520 billion by the year 2024. Recombinant proteins are a critical component of many biopharmaceuticals, making up approximately 60% of all approved biologic drugs. Recombinant proteins are proteins that are produced using recombinant DNA technology, also known as genetic engineering. This technology involves the insertion of a gene encoding a specific protein into a host organism, such as bacteria, yeast, or mammalian cells, which then produces the protein of interest. Recombinant proteins are used in a wide range of applications, including biopharmaceuticals, research and development, diagnostics, and industrial processes.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~12.80% |
|
Base Year Market Size (2023) |
~ USD 2 Billion |
|
Forecast Year Market Size (2035) |
~ USD 9 Billion |
|
Regional Scope |
|
Application (Research, Therapeutics, Healthcare)
The global recombinant proteins market is segmented and analyzed for demand and supply by application into research, therapeutics, and healthcare. Out of the three types of applications, the healthcare segment is estimated to gain the largest market share of about ~35% in the year 2035. The growth of the segment can be accredited to the presence of large number of patients in the healthcare industry, which is expanding notably. The hospitals in the healthcare sector are also growing rapidly in number. For instance, by the year 2022 there was noted to be approximately 6,100 hospitals in the United States. Hospitals provide a wide range of medical care. Physicians, called hospital doctors, typically specialize in internal medicine, pediatrics, or general practice. They have the knowledge to solve common problems and the resources to solve more complex medical problems. Hospitals may also offer specialized care, such as neurology, obstetrics and gynecology, and oncology. By definition of a hospital, a county hospital is typically a primary medical facility in a region with numerous intensive care and mobile beds for patients requiring long-term care.
Host Cell (Insect Cells, Mammalian)
The global recombinant proteins market is also segmented and analyzed for demand and supply by host cell into insect cells, and mammalian. Amongst these two segments, the mammalian segment is expected to garner a significant share of around ~60% in the year 2035. The growth of the segment can be accredited to the increasing demand for biologics. Biologics, including monoclonal antibodies and other complex proteins, are increasingly being used to treat a range of diseases, such as cancer and autoimmune disorders. The mammalian cell expression system is well-suited to produce these complex proteins, driving demand for the mammalian segment in the global recombinant protein market. The mammalian cell expression system is a commonly used platform for the production of recombinant proteins due to its ability to produce complex proteins with post-translational modifications similar to those found in human cells. Advances in technology, such as genetic engineering and cell line development, have improved the efficiency and productivity of the mammalian cell expression system, making it a more attractive platform for the production of recombinant proteins. The biopharmaceutical industry is growing rapidly, driven by the increasing demand for biologics. This growth is expected to continue, driving demand for the mammalian segment over the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Host Cell |
|
|
By Application |
|
North American Market Forecast
The recombinant proteins in the North America region, amongst the market in all the other regions, is projected to hold the largest market share of about ~35% by the end of 2035. The regional growth can majorly be attributed to the growing population and research activity, health insurance covering various cancer diagnoses and related treatments requiring recombinant proteins. Rising economic status and affordability of advanced treatments for patients are estimated to boost the growth of the market in the region during the forecast period. According to the U.S. Bureau of Economic Analysis, personal income in the U.S. in August 2022 grew at a rate of 0.3% to reach USD 71.6 billion, while personal spending was observed to grow at a rate of 0.4% to reach USD 6.75 billion. In the United States, 1,752,735 new cancer cases were reported in 2019 and 599,589 people died from cancer, which is a chronic disease. Moreover, the insurance companies in North America offer efficient reimbursement policies to the patients going through treatment of chronic diseases, which encourages the patients to opt for advanced treatment methods. Hence, this is also estimated to add to the regional market growth significantly.
APAC Market Statistics
The recombinant proteins in the Asia Pacific region, amongst the market in all the other regions, is projected to hold the second largest share of about ~24% during the forecast period. The growth of the market in this region can primarily be attributed to the increasing demand for biopharmaceuticals. The demand for biopharmaceuticals is increasing rapidly in the Asia Pacific region, driven by the increasing prevalence of chronic diseases and the aging population. Biopharmaceuticals, including recombinant proteins, are being used to treat a range of diseases such as cancer, diabetes, and autoimmune disorders. The biotech industry in the Asia Pacific region is rapidly growing, driven by government initiatives and increasing investment in research and development. This growth is creating opportunities for the development and production of recombinant proteins. Many biopharmaceutical companies in the US and Europe are outsourcing their research and development activities to the Asia Pacific region owing to lower costs and favorable regulatory environments. This outsourcing is anticipated to drive the growth of the recombinant proteins market in the region.
Europe Market Forecast
Further, the recombinant proteins in the Europe region, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of the market can be attributed majorly to the advancements in technology in the region. Europe is home to some of the world's leading biopharmaceutical companies, and these companies are investing heavily in research and development to improve the efficiency and productivity of the production of recombinant proteins. This investment is driving the growth of the regional market. Europe has a well-established regulatory framework for the development and production of biopharmaceuticals, including recombinant proteins. This framework has encouraged investment in the region and contributed to the growth of the market. The biotech industry in Europe is growing rapidly, driven by government initiatives and increasing investment in research and development. This growth is creating opportunities for the development and production of recombinant proteins. Overall, the recombinant proteins market in Europe is expected to continue to grow steadily, driven by increasing demand for biopharmaceuticals, advancements in technology, and favorable regulatory environments.
Merck KGaA: Merck announced that it had signed an agreement to acquire AmpTec, a leading provider of high-quality RNA and mRNA for research and commercial applications. The acquisition will strengthen Merck's capabilities in the field of mRNA-based therapeutics and vaccines.
Roche Holdings Inc.: Roche announced that it had received approval from the US Food and Drug Administration (FDA) for its recombinant protein Hemlibra, for the treatment of hemophilia A in patients without factor VIII inhibitors. Hemlibra is a bispecific antibody designed to bring together factors IXa and X, which are needed to activate the natural coagulation cascade and restore the blood clotting process.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?